Pinealon
NootropicsPreclinicalAlso known as: EDR
Pinealon is a synthetic tripeptide — glutamyl-aspartyl-arginine (Glu-Asp-Arg, or EDR) — developed by the St Petersburg Institute of Bioregulation and Gerontology (IBG) under the leadership of Professor Vladimir Khavinson, the dominant figure in what is collectively known as the "Russian short-peptide bioregulator" school of research. Pinealon was designed as a peptide analog of signaling molecules found in natural extracts of the pineal gland, specifically a class of bioactive compounds that Khavinson's group began isolating and characterizing in the late 1980s as "cytomedins" — short peptides extracted from specific animal tissues and claimed to carry tissue-specific regulatory signals back to the corresponding tissue type. The Khavinson framework is as follows: the pineal gland, like other endocrine and parenchymal organs, contains short regulatory peptides that are involved in cell differentiation, gene expression regulation, and tissue homeostasis.
Overview
At A Glance
The proposed mechanism of Pinealon is rooted in the Khavinson school's broader theory of short-peptide tissue-specific bioregulation. The full theory is worth understanding because it underlies all twelve Russian bioregulator compounds in this catalog.…
Mechanism of Action
The proposed mechanism of Pinealon is rooted in the Khavinson school's broader theory of short-peptide tissue-specific bioregulation. The full theory is worth understanding because it underlies all twelve Russian bioregulator compounds in this catalog.
The Khavinson short-peptide bioregulator theory:
-
Tissue-specific short peptides exist endogenously. Cells in differentiated tissues produce and release short regulatory peptides (typically 2–4 amino acids) as signaling molecules. These peptides are claimed to be involved in tissue homeostasis, cell differentiation, and response to injury.
-
Synthetic analogs retain tissue-specific activity. When the short peptide sequences are synthesized and administered exogenously, they are claimed to reach the corresponding tissue and modulate gene expression and cellular function in a tissue-selective manner.
-
Direct gene-expression regulation. Khavinson's group has published work suggesting that short peptides can penetrate cell membranes (likely via peptide transporters or direct membrane permeability for small, charged molecules) and enter the nucleus, where they are proposed to bind specific DNA sequences at gene promoters or act on histones to modulate transcription. Papers in the 2000s from Khavinson and colleagues describe proposed binding of short peptides to specific DNA motifs using computational docking and NMR evidence.
-
Cellular effects include:
- Modulation of proliferation and differentiation in tissue-specific cell populations
- Influence on telomerase activity (most famously for Epitalon, which is claimed to upregulate telomerase in human somatic cells)
- Anti-inflammatory and antioxidant effects via downstream gene expression changes
- Interactions with heat shock proteins and cellular stress response pathways
Specific to Pinealon (Glu-Asp-Arg):
- Pinealon was derived from a peptide extract of bovine pineal gland called "Epiphamine" or "pineal polypeptide extract," which was first characterized by Khavinson's group in the 1980s–1990s.
- The Glu-Asp-Arg sequence was identified as biologically active within that extract and subsequently synthesized for research and clinical use.
- Proposed targets include neuronal cells in the central nervous system, where Pinealon is claimed to:
- Protect against oxidative stress (reducing reactive oxygen species and lipid peroxidation)
- Support mitochondrial function in neurons
- Upregulate neurotrophic factor expression (BDNF, NGF)
- Support circadian regulation through pineal-related signaling
- Protect against beta-amyloid and related neurotoxicity in models of Alzheimer's disease
- Influence sleep regulation via melatonin-adjacent pathways
Published mechanistic work:
- Khavinson and Kuznik (2011) and related reviews from the Khavinson group describe the theoretical framework and cite multiple preclinical studies of Pinealon and related peptides.
- Arutjunyan et al. (2012) reported protective effects of Pinealon against hypoxia-induced neuronal damage in cell culture models.
- Khavinson et al. (2012) described effects of Pinealon on cognitive function in aged animals.
- Russian-language publications in Uspekhi Gerontologii and Klinicheskaya Gerontologiya have extended these findings into clinical gerontology populations.
The replication question:
- Independent Western labs have confirmed some in-vitro cellular effects of short peptides (including a subset of the Khavinson peptides) but have not systematically replicated the dramatic clinical outcomes described in Russian literature.
- The claim that short peptides directly bind DNA and act as transcription regulators is theoretically plausible but has not been conclusively demonstrated with the rigor that would be expected in a modern molecular biology framework.
- The claim that Pinealon specifically reaches the brain after peripheral administration (subcutaneous or intranasal) in sufficient concentration to exert these effects has not been validated with modern pharmacokinetic methods in most target tissues.
Honest mechanism summary:
Pinealon is a short peptide with plausible but not fully validated mechanisms of neuroprotection, supported primarily by Khavinson-lab publications and limited independent replication. Cellular-level effects in simple in-vitro systems are reasonably well-documented; whole-organism pharmacokinetics and the most dramatic clinical claims are less well-supported. For readers with a strong mechanistic bias toward Western-validated pathways, this compound requires a higher trust threshold in Russian gerontology literature than a typical Western-approved drug.
Overview
Pinealon is a synthetic tripeptide — glutamyl-aspartyl-arginine (Glu-Asp-Arg, or EDR) — developed by the St Petersburg Institute of Bioregulation and Gerontology (IBG) under the leadership of Professor Vladimir Khavinson, the dominant figure in what is collectively known as the "Russian short-peptide bioregulator" school of research. Pinealon was designed as a peptide analog of signaling molecules found in natural extracts of the pineal gland, specifically a class of bioactive compounds that Khavinson's group began isolating and characterizing in the late 1980s as "cytomedins" — short peptides extracted from specific animal tissues and claimed to carry tissue-specific regulatory signals back to the corresponding tissue type.
The Khavinson framework is as follows: the pineal gland, like other endocrine and parenchymal organs, contains short regulatory peptides that are involved in cell differentiation, gene expression regulation, and tissue homeostasis. When these natural peptides are purified, sequenced, and synthetic analogs are produced (the short-peptide analogs being the most studied), the synthetic peptides retain the ability to influence the same tissue from which they were derived. Pinealon, as the pineal-derived tripeptide bioregulator, is claimed to act on neural tissue — particularly the brain — to support neuroprotection, cognitive function, circadian regulation, and protection against age-related neurodegeneration.
A substantial body of Russian-language clinical and preclinical literature supports these claims, going back to the 1990s and continuing through 2026. The work has been led by Khavinson and his collaborators at the Mechnikov North-Western State Medical University in St Petersburg, published in Russian medical journals (Uspekhi Gerontologii, Bulletin of Experimental Biology and Medicine) and selected Western journals (Neuroendocrinology Letters, Biogerontology). Outside Russia, Pinealon is part of a broader group of short-peptide bioregulators that includes Epitalon, Thymogen, Thymalin, Vilon, Livagen, and others — each claimed to be organ-specific based on the source tissue of the original natural peptide extract.
The Western biomedical community has given Khavinson's work a mixed reception. On the positive side, the theoretical framework — that short peptides could function as tissue-specific gene-expression modulators — is scientifically coherent, and a subset of the claims (particularly around Epitalon and telomere biology) has attracted genuine interest and some independent replication. On the skeptical side, the clinical datasets are predominantly Russian, the independent replication of the most dramatic outcomes is thin, the peptides have never been through standard Western regulatory approval processes, and the commercial availability in Russia through the "Cytogen" brand (Cytomed) and various gerontology clinics has driven a significant body-hacking export market without corresponding Western clinical validation.
This entry takes the honest position that Pinealon — and the broader Russian short-peptide bioregulator category — represents a plausible mechanism of action with real Russian clinical use, limited Western replication, and a research-grade user experience outside Russia. It is not FDA-approved, not widely available through Western prescription pharmacies, and carries the full research-chemical status in most Western jurisdictions. Users engaging with Pinealon are effectively trusting Khavinson's lab and its affiliated clinical collaborators, without the standard Western regulatory and replication infrastructure.
For readers exploring the Khavinson peptide space, see also Epitalon, Thymogen, Cartalax, Vilon, and related entries. For comparison with other short-peptide neuroprotective compounds, see Cerebrolysin (a larger neuropeptide preparation), Semax (Russian ACTH-derived peptide), and Selank.
Chemical Information
IUPAC Name
L-Glutamyl-L-aspartyl-L-arginine
CAS Number
Not yet available
Molecular Formula
Glu-Asp-Arg
Molecular Mass
417.39 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Interaction Matrix
Contraindications
Absolute contraindications:
- Pregnancy and lactation — no data on developmental effects
- Pediatric use (under 18) — not studied; claimed to affect neural development
- Known hypersensitivity to Pinealon or peptide products
- Active seizure disorder without neurologic management
- Active CNS infection (meningitis, encephalitis)
- Recent severe head trauma (within 3 months)
- Active hormone-sensitive cancer without oncologic evaluation (pineal/melatonin pathway involvement)
- Severe mental illness (acute psychosis, suicidality) without psychiatric supervision
- Users unable to access reputable source with verified purity
- Users unable to perform or access safe injection technique
Relative contraindications requiring cautious approach:
- History of seizures or epilepsy
- Active or recent psychiatric illness (depression, anxiety, bipolar) — theoretical CNS interactions
- Autoimmune disease — Khavinson peptides claim immune-modulating effects; effects in active autoimmunity unclear
- Organ transplant recipients on immunosuppression
- Active systemic infection
- Uncontrolled thyroid disease
- Severe sleep disorder (especially parasomnias) — may be worsened by circadian-affecting peptides
- Bleeding disorder or anticoagulation (injection site concerns)
- Recent cardiac event
- Advanced renal or hepatic disease
Drug interactions (theoretical — limited formal data):
- Melatonin — pineal-derived, theoretical additive or redundant effects; no documented adverse interaction
- Antipsychotics and antidepressants — unclear; monitor for CNS effects
- Mood stabilizers (lithium, valproate) — unclear interactions
- Sleep medications (benzodiazepines, z-drugs, trazodone) — unclear interactions
- Immunosuppressants — theoretical interaction with immune-modulating Khavinson peptide effects
- Cognitive enhancers (cholinesterase inhibitors, memantine) — unclear interactions; generally considered compatible
- Hormone therapies — unclear; theoretical pineal-hormone axis involvement
- Anticoagulants and antiplatelets — injection-site bleeding risk; generally manageable
Populations requiring specialist oversight:
- Patients with neurodegenerative disease (Alzheimer's, Parkinson's) — may be appropriate candidates but require neurologic evaluation and monitoring
- Patients with psychiatric comorbidities
- Athletes in tested sport (verify Pinealon's current WADA status for their sport)
- Patients with history of cancer, particularly pineal or CNS tumors
- Patients with autoimmune disease
Baseline evaluation before starting Pinealon:
- Full history and physical examination
- CBC, CMP, lipid panel, A1c, thyroid panel
- Comprehensive hormonal panel if relevant to patient age and gender
- Inflammatory markers (hs-CRP)
- Consider cognitive testing baseline (if intended target is cognitive support)
- Review of concurrent medications and supplements
- Family history review (neurodegenerative disease, cancer, autoimmune)
Monitoring during Pinealon use:
- Subjective symptom tracking daily during cycles
- Sleep quality and mood tracking
- Injection site assessment
- Any new neurologic symptoms — headache, vision change, motor change, cognitive decline — warrant immediate discontinuation and evaluation
- Periodic (annual or semi-annual) repeat of baseline labs for trends
When to discontinue immediately:
- Any severe adverse reaction (anaphylaxis, severe allergic response)
- Seizure or seizure-like event
- New or worsening psychiatric symptoms
- Persistent headache or neurologic symptoms
- Injection site infection or systemic symptoms
- Any concerning laboratory change
- Pregnancy confirmed or planned
Doping and sport considerations:
- Pinealon is not currently on the WADA prohibited list (verify at time of use for specific sport rules)
- However, research-chemical peptides carry contamination risk that can cause positive tests for other substances
- Tested athletes should verify peptide purity or consider avoiding altogether
Long-term safety considerations:
- Multi-decade safety data on Pinealon specifically does not exist outside Russian clinical practice
- Any user committing to long-term Khavinson peptide use should periodically reassess:
- Whether biomarkers remain stable or improved
- Whether new symptoms have emerged
- Whether the research-chemical risk continues to be justified by the benefit
- Whether their health has materially improved, plateaued, or declined
Interaction with other Khavinson peptides:
- Stacking multiple Khavinson peptides is common in the user community
- No formal interaction data exists
- Conservative approach: start with one peptide, establish response and tolerability, then gradually add others with attention to cumulative effects
Special consideration — pineal health:
- Pinealon's origin as a pineal peptide raises theoretical questions about effects on pineal function
- In healthy individuals, this is not a known concern
- In individuals with pineal pathology (cysts, tumors) or pineal surgical history, the compound should be avoided without specialist evaluation
The contraindication summary: Pinealon has a reasonable safety profile in the available Russian clinical literature, but the evidence base is not strong enough to rule out rare or delayed adverse effects. The compound is best approached as a research-grade intervention with modest and pulsed dosing, reputable sourcing, appropriate monitoring, and willingness to discontinue if concerns emerge. For users whose medical history includes any of the absolute contraindications, Pinealon should not be used. For users with relative contraindications, specialist consultation is warranted.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$36.99
up to $45.00
$4.5000
2
2
strip, vial
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
Pinealon 10mg | vial | 1 vial● In Stock | $45.00BEST | $4.500 | — | |
| Brain Fuel Dissolving Strips | strip | 1 pack● In Stock | $36.99 | $7.398 | — |
Tracking since Apr 6, 2026 · 4 data points
Price History
3 data pointsVendors Selling Pinealon
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View All9-MBC (9-Methyl-β-carboline)
NootropicsPreclinical9-Methyl-β-carboline (9-MBC) is a synthetic β-carboline alkaloid that has gained significant interest in the nootropic community for its reported ability to promote dopaminergic neuron growth, increase dopamine synthesis enzymes, and provide neuroprotective effects against neurotoxins.
Bromantane
NootropicsRussia ApprovedBromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.
Dihexa
NootropicsPreclinicalDihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.
Kavain
NootropicsPreclinicalActive compound from kava for relaxation and sleep support..
L-Theanine
NootropicsFDA ApprovedL-Theanine is a non-proteinogenic amino acid found almost exclusively in tea (Camellia sinensis) and a handful of edible mushrooms, and it has become the single most widely-used calm-focus nootropic in the modern supplement market — both on its own at 100-400mg doses and, even more prominently, as the classic 1:1 or 2:1 pair with caffeine that defines the "calm-focus" experiential signature of green tea and of virtually every serious nootropic stack.
L-Tyrosine
NootropicsPreclinicalL-Tyrosine is a non-essential aromatic amino acid and the direct biosynthetic precursor to the catecholamine neurotransmitters dopamine, norepinephrine, and epinephrine.
Side-by-Side Comparisons
All ComparisonsView Full Dosage Guide →
Protocols, calculator & safety for Pinealon
Related Articles
All PostsResearch Score
21 PubMed studies
Quality Indicators
Data Completeness
100%Research Credibility
Quick Facts
Molecular Weight
417.39 g/mol
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
Is Pinealon safe?
Pinealon appears to be reasonably well-tolerated in the available Russian clinical literature and user-reported experience, with mild side effects being most common. However, the evidence base is limited compared to Western-approved drugs — most clinical studies are from a single research group (Khavinson's lab at the St Petersburg Institute of Bioregulation and Gerontology), published primarily in Russian-language journals, with limited independent Western replication. Long-term safety data over decades of use exists mainly within Russian clinical gerontology practice rather than from controlled Western studies. Users should treat it as a research-grade intervention with appropriate humility about what is and isn't known.
What does Pinealon actually do?
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) derived from bovine pineal gland extract research, claimed to support neuroprotection, cognitive function, circadian regulation, and protection against age-related neurodegeneration. The proposed mechanism, per the Khavinson short-peptide bioregulator theory, is direct modulation of gene expression in neural tissue — though this mechanism has limited independent molecular biology validation. User-reported effects are typically subtle: slight improvements in mental clarity, sleep quality, and subjective energy during and after dosing cycles. Dramatic subjective effects are unusual and sometimes reflect placebo or product-quality variables.
How is Pinealon related to Epitalon and other Khavinson peptides?
Pinealon, Epitalon, Thymalin, Thymogen, Vilon, Livagen, Cartalax, and others are all products of the St Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson. They share a common theoretical framework — short peptide bioregulators with claimed tissue-specific effects — and are typically produced and distributed through the same Russian clinical and commercial channels (Cytomed, Cytogen brand). Each peptide is claimed to target a different organ system: Pinealon (brain/pineal), Epitalon (pineal/telomeres), Thymalin/Thymogen (thymus/immunity), Cartalax (cartilage), Livagen (liver), and so on. Stacking multiple Khavinson peptides is common in the user community.
Is Pinealon legal and how do I get it?
Pinealon is not FDA-approved, not EMA-approved, and not available through Western prescription pharmacies for general use. In Russia, it is available through gerontology clinics and the Cytomed Cytogen brand. Outside Russia, it is typically obtained through research-chemical peptide suppliers, where legal status varies by jurisdiction — in most countries, personal research use occupies a gray area, while sale as a supplement or drug is not authorized. Users should understand customs risks and source from reputable research-peptide vendors with certificates of analysis. For related Russian peptides available through similar channels, see Semax and Selank.
How do I use Pinealon — what's the typical protocol?
The standard Khavinson-style protocol is pulsed rather than continuous: 10–20 day cycles of daily subcutaneous injection (2–5 mg per day), administered in the morning, with 60–90 day washouts between cycles. Most users run 2–4 cycles per year. An intranasal alternative at 150–500 mcg per nostril daily is sometimes used. Cycles can be run alone or in combination with other Khavinson peptides (most commonly paired with Epitalon). Begin at the lower end of the dose range, complete a full cycle before assessing, and increase only if response is inadequate. See the protocol sections above for beginner/intermediate/advanced details.
Will Pinealon help with Alzheimer's or cognitive decline?
Russian preclinical and clinical literature describes positive effects of Pinealon on cognitive function in aged animals and humans, including some studies in Alzheimer's-model systems and aging populations. These findings have not been systematically replicated in Western multi-center RCTs, and Pinealon is not an approved treatment for Alzheimer's disease in any jurisdiction. For individuals with diagnosed cognitive impairment or dementia, standard-of-care treatments (cholinesterase inhibitors, memantine, new anti-amyloid biologics where appropriate, lifestyle and cardiovascular optimization) should be the foundation. Pinealon may be a reasonable adjunct for users engaged with gerontology-informed protocols, but should not substitute for appropriate medical care.
What's the difference between Pinealon and melatonin?
Pinealon is a synthetic tripeptide (Glu-Asp-Arg); melatonin is a monoamine hormone (N-acetyl-5-methoxytryptamine). Both are associated with the pineal gland — Pinealon is derived from pineal peptide extracts while melatonin is the primary pineal hormone involved in circadian regulation. Pinealon's claimed mechanism is gene-expression regulation in neural tissue, while melatonin's mechanism is receptor binding (MT1 and MT2 melatonin receptors). The two can be used together in theory, and some users report additive benefits on sleep and circadian rhythm, but formal interaction data is limited. Melatonin is widely available, inexpensive, and well-characterized; Pinealon is a research-grade peptide with a narrower evidence base.
Can Pinealon cause any sleep changes?
Pinealon is claimed to have circadian-supportive effects and is most often used in the morning to align with its proposed pineal-axis mechanism. User reports include improved sleep quality in some individuals and mild insomnia (particularly if dosed in the evening) in others. Dosing timing matters: morning administration is the convention, and evening dosing should be avoided. Users with active sleep disorders (parasomnias, severe insomnia, sleep apnea) should approach Pinealon cautiously and prioritize resolving the underlying sleep issue through appropriate medical channels first.
How does Pinealon compare to Semax or Selank?
Semax and Selank are also Russian peptides with cognitive and mood-supporting effects, but they come from different research programs and have different mechanisms. Semax is an ACTH4-7 analog (MEHFPGP) developed for acute neuroprotection and cognitive enhancement; it has stronger Western research validation than Khavinson peptides and is more immediately noticeable in subjective effect. Selank is a neuroprotective anxiolytic peptide (TKPRPGP) derived from tuftsin; it has antianxiety and mild cognitive effects. Pinealon is from the Khavinson school with pulsed-dosing convention; its effects are more subtle and cumulative. Users often stack Pinealon cycles with daily Semax and Selank use for complementary effects.
What should I actually do if I want to support cognitive aging?
Start with the fundamentals that have the strongest evidence: regular aerobic exercise (150+ minutes per week), resistance training (2–3x per week), Mediterranean or MIND dietary pattern, 7–9 hours of quality sleep per night, social and intellectual engagement, stress management, and management of cardiovascular risk factors (blood pressure, lipids, glucose). Add evidence-based nutritional support: omega-3 EPA/DHA, vitamin D if deficient, adequate B12 and folate, creatine monohydrate (5 g/day, showing emerging cognitive benefit), and targeted supplementation based on labs. Consider approved cognitive pharmacotherapy if indicated (for diagnosed conditions). Research-grade interventions like Pinealon, Epitalon, Semax, and Selank are reasonable additions for users with the risk tolerance, monitoring capacity, and financial resources to engage with research-chemical peptides. For broader longevity and cognitive optimization strategies, see /stack and the full compound library.
Research Tools
Related Compounds
View All9-MBC (9-Methyl-β-carboline)
NootropicsPreclinical9-Methyl-β-carboline (9-MBC) is a synthetic β-carboline alkaloid that has gained significant interest in the nootropic community for its reported ability to promote dopaminergic neuron growth, increase dopamine synthesis enzymes, and provide neuroprotective effects against neurotoxins.
Bromantane
NootropicsRussia ApprovedBromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.
Dihexa
NootropicsPreclinicalDihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.
Kavain
NootropicsPreclinicalActive compound from kava for relaxation and sleep support..
L-Theanine
NootropicsFDA ApprovedL-Theanine is a non-proteinogenic amino acid found almost exclusively in tea (Camellia sinensis) and a handful of edible mushrooms, and it has become the single most widely-used calm-focus nootropic in the modern supplement market — both on its own at 100-400mg doses and, even more prominently, as the classic 1:1 or 2:1 pair with caffeine that defines the "calm-focus" experiential signature of green tea and of virtually every serious nootropic stack.
L-Tyrosine
NootropicsPreclinicalL-Tyrosine is a non-essential aromatic amino acid and the direct biosynthetic precursor to the catecholamine neurotransmitters dopamine, norepinephrine, and epinephrine.
Side-by-Side Comparisons
All ComparisonsCompare Pinealon head-to-head: mechanism, half-life, dosing, safety, and live pricing.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
